치과용 멤브레인 및 골이식 대체물 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 지역별, 부문별 예측(2025-2033년)

Dental Membrane And Bone Graft Substitutes Market Summary

The global dental membrane and bone graft substitutes market size was valued at USD 1.47 billion in 2024 and is projected to reach USD 2.96 billion by 2033, growing at a CAGR of 8.19% from 2025 to 2033. The demand for dental membranes and bone graft substitutes is rising owing to the increasing burden of dental disorders and the growing demand for aesthetic and restorative dental procedures.

In addition, increasing dental tourism is also expected to propel market growth. The rising global prevalence of dental disorders, including periodontal disease, tooth decay, tooth loss, and oral cancer, significantly drives demand in the dental membrane and bone graft substitutes market. According to World Health Organization data published in March 2025, more than 1 billion people suffer from severe periodontal disease worldwide. Additionally, about 7% of adults aged 20 and above and around 23% of those over 60 experience complete tooth loss, often requiring implants and bone regeneration procedures. These statistics underscore the growing necessity for dental implants and bone regeneration procedures, as tooth loss frequently leads to jawbone deterioration, requiring bone graft substitutes and membranes to support successful implant integration.

Moreover, the increasing incidence of oral cancer is anticipated to boost the demand for dental bone grafts further. During surgical treatment for oral cancer, bone grafts are frequently required to reconstruct and restore areas of the jawbone that have been damaged or removed during tumor excision. This underscores the vital role that bone graft substitutes play in facilitating successful surgical outcomes and post-operative rehabilitation.

Furthermore, the rising demand for restorative and aesthetic dental procedures like dental implantation is anticipated to significantly drive the growth of the dental membrane and bone graft substitutes market. When bone is insufficient to support an implant securely, bone grafting becomes essential. In addition, a dental membrane protects the graft site and prevents gum tissue from disrupting bone regeneration, thereby enhancing healing and improving graft success rates. As the preference for procedures like dental implantation continues to grow, so does the demand for supportive materials such as dental membranes and bone graft substitutes. According to a study published by Twin Dental New York in June 2025, about 5 million new dental implants are placed yearly in the U.S. alone. Thus, the significant population undergoing dental implantation is anticipated to drive the demand for dental membranes and bone graft substitutes.

Global Dental Membrane And Bone Graft Substitutes Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global dental membrane and bone graft substitutes market report based on product, application, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Bone Graft Substitutes (BGS)
  • Allograft
  • Demineralized Bone Matrix
  • Others
  • Autograft
  • Xenograft
  • Bovine Derived
  • Porcine Derived
  • Others
  • Synthetic
  • Hydroxyapatite (HA)
  • Tricalcium Phosphate (TCP)
  • Bioactive Glass
  • Others
• Dental Membranes and Soft Tissue Regeneration Materials
  • Resorbable Membranes
  • Bovine -derived collagen based
  • Porcine derived collagen based
  • Others
  • Non- Resorbable Membrane
  • Expanded PTFE (ePTFE)
  • Dense PTFE (dPTFE)
  • Titanium-Reinforced PTFE
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Ridge Augmentation
• Sinus Lift
• Periodontal Defect Regeneration
• Implant Bone Regeneration
• Socket Preservation
• Soft Tissue Regeneration
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Application
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Dental Membrane And Bone Graft Substitutes Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising burden of dental disorders
    • 3.2.1.2. Development of synthetic bone grafts
    • 3.2.1.3. Growing demand for aesthetic and restorative dental procedures
    • 3.2.1.4. Increasing dental tourism
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of dental treatments
    • 3.2.2.2. Potential risks and complications associated with dental procedures
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Increasing number of clinical trials
    • 3.2.3.2. Growing development & approvals of resorbable membranes
    • 3.2.3.3. Expansion into synthetic membrane
    • 3.2.3.4. Strategic partnerships & investment to enhance market presence
    • 3.2.3.5. Expansion opportunities in emerging economies
    • 3.2.3.6. Increasing demand for composite bone grafts
    • 3.2.3.7. Growing focus on 3D printed and custom grafts
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Regulatory and approval complexities
    • 3.2.4.2. Economic and currency exchange risks
• 3.3. Dental Membrane And Bone Graft Substitutes Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. Dental Membrane And Bone Graft Substitutes Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Dental Membrane And Bone Graft Substitutes Market Product Movement Analysis
• 4.3. Global Dental Membrane And Bone Graft Substitutes Market Size & Trend Analysis, by Product 2021 to 2033 (USD Million)
• 4.4. Bone Graft Substitutes (BGS)
  • 4.4.1. Bone graft substitutes (BGS) market estimates and forecasts for 2021 to 2033 (USD Million)
    • 4.4.1.1. Allograft
      • 4.4.1.1.1. Allograft market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.4.1.1.1.1. Demineralized Bone Matrix
          • 4.4.1.1.1.1.1. Demineralized bone matrix market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.4.1.1.1.2. Others
          • 4.4.1.1.1.2.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
    • 4.4.1.2. Autograft
      • 4.4.1.2.1. Autograft market estimates and forecasts for 2021 to 2033 (USD Million)
    • 4.4.1.3. Xenograft
      • 4.4.1.3.1. Xenograft market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.4.1.3.1.1. Bovine Derived
          • 4.4.1.3.1.1.1. Bovine derived market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.4.1.3.1.2. Porcine Derived
          • 4.4.1.3.1.2.1. Porcine derived market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.4.1.3.1.3. Others
          • 4.4.1.3.1.3.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
    • 4.4.1.4. Synthetic
      • 4.4.1.4.1. Synthetic market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.4.1.4.1.1. Hydroxyapatite (HA)
          • 4.4.1.4.1.1.1. Hydroxyapatite (HA) market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.4.1.4.1.2. Tricalcium Phosphate (TCP)
          • 4.4.1.4.1.2.1. Tricalcium phosphate (TCP) market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.4.1.4.1.3. Bioactive Glass
          • 4.4.1.4.1.3.1. Bioactive glass market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.4.1.4.1.4. Others
          • 4.4.1.4.1.4.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
• 4.5. Dental Membranes and Soft Tissue Regeneration Materials
  • 4.5.1. Dental membranes and soft tissue regeneration materials market estimates and forecasts for 2021 to 2033 (USD Million)
    • 4.5.1.1. Resorbable membranes
      • 4.5.1.1.1. Resorbable membranes market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.5.1.1.1.1. Bovine -derived collagen based
          • 4.5.1.1.1.1.1. Bovine -derived collagen based market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.5.1.1.1.2. Porcine derived collagen based
          • 4.5.1.1.1.2.1. Porcine derived collagen based market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.5.1.1.1.3. Others
          • 4.5.1.1.1.3.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
    • 4.5.1.2. Non resorbable membranes
      • 4.5.1.2.1. Non resorbable membranes market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.5.1.2.1.1. Expanded PTFE (ePTFE)
          • 4.5.1.2.1.1.1. Expanded PTFE (ePTFE) market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.5.1.2.1.2. Dense PTFE (dPTFE)
          • 4.5.1.2.1.2.1. Dense PTFE (dPTFE) market estimates and forecasts for 2021 to 2033 (USD Million)
        • 4.5.1.2.1.3. Titanium-Reinforced PTFE
          • 4.5.1.2.1.3.1. Titanium-reinforced PTFE market estimates and forecasts for 2021 to 2033 (USD Million)

Chapter 5. Dental Membrane And Bone Graft Substitutes Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Dental Membrane And Bone Graft Substitutes Market Application Movement Analysis
• 5.3. Global Dental Membrane And Bone Graft Substitutes Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Ridge Augmentation
  • 5.4.1. Ridge augmentation market estimates and forecast 2021 to 2033 (USD Million)
• 5.5. Sinus Lift
  • 5.5.1. Sinus lift market estimates and forecast 2021 to 2033 (USD Million)
• 5.6. Periodontal Defect Regeneration
  • 5.6.1. Periodontal defect regeneration market estimates and forecast 2021 to 2033 (USD Million)
• 5.7. Implant Bone Regeneration
  • 5.7.1. Implant bone regeneration market estimates and forecast 2021 to 2033 (USD Million)
• 5.8. Socket Preservation
  • 5.8.1. Socket preservation market estimates and forecasts for 2021 to 2033 (USD Million)
• 5.9. Soft Tissue Regeneration
  • 5.9.1. Soft tissue regeneration market estimates and forecast 2021 to 2033 (USD Million)
• 5.10. Others
  • 5.10.1. Others market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Dental Membrane And Bone Graft Substitutes Market: Regional Estimates & Trend Analysis By Product and By Application

• 6.1. Regional Dashboard
• 6.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 6.3. North America
  • 6.3.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Competitive scenario
    • 6.3.2.3. Regulatory framework
    • 6.3.2.4. Reimbursement scenario
    • 6.3.2.5. U.S. market estimates and forecasts, 2021 - 2033
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Competitive scenario
    • 6.3.3.3. Regulatory framework
    • 6.3.3.4. Reimbursement scenario
    • 6.3.3.5. Canada market estimates and forecasts, 2021 - 2033
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Competitive scenario
    • 6.3.4.3. Regulatory framework
    • 6.3.4.4. Reimbursement scenario
    • 6.3.4.5. Mexico market estimates and forecasts, 2021 - 2033
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Competitive scenario
    • 6.4.1.3. Regulatory framework
    • 6.4.1.4. Reimbursement scenario
    • 6.4.1.5. UK market estimates and forecasts, 2021 - 2033
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Competitive scenario
    • 6.4.2.3. Regulatory framework
    • 6.4.2.4. Reimbursement scenario
    • 6.4.2.5. Germany market estimates and forecasts, 2021 - 2033
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Competitive scenario
    • 6.4.3.3. Regulatory framework
    • 6.4.3.4. Reimbursement scenario
    • 6.4.3.5. France market estimates and forecasts, 2021 - 2033
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Competitive scenario
    • 6.4.4.3. Regulatory framework
    • 6.4.4.4. Reimbursement scenario
    • 6.4.4.5. Italy market estimates and forecasts, 2021 - 2033
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Competitive scenario
    • 6.4.5.3. Regulatory framework
    • 6.4.5.4. Reimbursement scenario
    • 6.4.5.5. Spain market estimates and forecasts, 2021 - 2033
  • 6.4.6. Denmark
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Competitive scenario
    • 6.4.6.3. Regulatory framework
    • 6.4.6.4. Reimbursement scenario
    • 6.4.6.5. Denmark market estimates and forecasts, 2021 - 2033
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Competitive scenario
    • 6.4.7.3. Regulatory framework
    • 6.4.7.4. Reimbursement scenario
    • 6.4.7.5. Sweden market estimates and forecasts, 2021 - 2033
  • 6.4.8. Norway
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Competitive scenario
    • 6.4.8.3. Regulatory framework
    • 6.4.8.4. Reimbursement scenario
    • 6.4.8.5. Norway market estimates and forecasts, 2021 - 2033
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Competitive scenario
    • 6.5.1.3. Regulatory framework
    • 6.5.1.4. Reimbursement scenario
    • 6.5.1.5. Japan market estimates and forecasts, 2021 - 2033
  • 6.5.2. India
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Competitive scenario
    • 6.5.2.3. Regulatory framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. India market estimates and forecasts, 2021 - 2033
  • 6.5.3. China
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Competitive scenario
    • 6.5.3.3. Regulatory framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. China market estimates and forecasts, 2021 - 2033
  • 6.5.4. South Korea
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Competitive scenario
    • 6.5.4.3. Regulatory framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. South Korea market estimates and forecasts, 2021 - 2033
  • 6.5.5. Australia
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Competitive scenario
    • 6.5.5.3. Regulatory framework
    • 6.5.5.4. Reimbursement scenario
    • 6.5.5.5. Australia market estimates and forecasts, 2021 - 2033
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Competitive scenario
    • 6.5.6.3. Regulatory framework
    • 6.5.6.4. Reimbursement scenario
    • 6.5.6.5. Thailand market estimates and forecasts, 2021 - 2033
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Competitive scenario
    • 6.6.1.3. Regulatory framework
    • 6.6.1.4. Reimbursement scenario
    • 6.6.1.5. Brazil market estimates and forecasts, 2021 - 2033
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Competitive scenario
    • 6.6.2.3. Regulatory framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. Argentina market estimates and forecasts, 2021 - 2033
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Competitive scenario
    • 6.7.1.3. Regulatory framework
    • 6.7.1.4. Reimbursement scenario
    • 6.7.1.5. South Africa market estimates and forecasts, 2021 - 2033
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Competitive scenario
    • 6.7.2.3. Regulatory framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Competitive scenario
    • 6.7.3.3. Regulatory framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. UAE market estimates and forecasts, 2021 - 2033
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Competitive scenario
    • 6.7.4.3. Regulatory framework
    • 6.7.4.4. Reimbursement scenario
    • 6.7.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Innovators
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Global Key company market share analysis, 2024
  • 7.3.4. Dentsply Sirona
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Bioteck S.p.A.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Maxigen Biotech Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Institut Straumann AG
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Nobel Biocare Services AG (Envista)
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Geistlich Holding
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. ZimVie Inc.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. NovaBone (Halma)
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Osteogenics Biomedical (Envista)
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Regenity
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Medtronic
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. BioHorizons
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. REGEDENT AG
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives
  • 7.3.17. IDL Dental Technologies LTD
    • 7.3.17.1. Company overview
    • 7.3.17.2. Financial performance
    • 7.3.17.3. Product benchmarking
    • 7.3.17.4. Strategic initiatives
  • 7.3.18. EUCARE PHARMACEUTICALS (P) LTD
    • 7.3.18.1. Company overview
    • 7.3.18.2. Financial performance
    • 7.3.18.3. Product benchmarking
    • 7.3.18.4. Strategic initiatives
  • 7.3.19. Curasan, Inc.
    • 7.3.19.1. Company overview
    • 7.3.19.2. Financial performance
    • 7.3.19.3. Product benchmarking
    • 7.3.19.4. Strategic initiatives
  • 7.3.20. TBR Dental
    • 7.3.20.1. Company overview
    • 7.3.20.2. Financial performance
    • 7.3.20.3. Product benchmarking
    • 7.3.20.4. Strategic initiatives
  • 7.3.21. DentiumUSA
    • 7.3.21.1. Company overview
    • 7.3.21.2. Financial performance
    • 7.3.21.3. Product benchmarking
    • 7.3.21.4. Strategic initiatives
  • 7.3.22. Tecnoss Dental Srl (Tecnoss s.r.l.)
    • 7.3.22.1. Company overview
    • 7.3.22.2. Financial performance
    • 7.3.22.3. Product benchmarking
    • 7.3.22.4. Strategic initiatives
  • 7.3.23. Unicare Biomedical, Inc.
    • 7.3.23.1. Company overview
    • 7.3.23.2. Financial performance
    • 7.3.23.3. Product benchmarking
    • 7.3.23.4. Strategic initiatives
  • 7.3.24. Neoss
    • 7.3.24.1. Company overview
    • 7.3.24.2. Financial performance
    • 7.3.24.3. Product benchmarking
    • 7.3.24.4. Strategic initiatives
  • 7.3.25. Advanced Medical Solutions Group plc
    • 7.3.25.1. Company overview
    • 7.3.25.2. Financial performance
    • 7.3.25.3. Product benchmarking
    • 7.3.25.4. Strategic initiatives
  • 7.3.26. B&B Dental Implant Company
    • 7.3.26.1. Company overview
    • 7.3.26.2. Financial performance
    • 7.3.26.3. Product benchmarking
    • 7.3.26.4. Strategic initiatives
  • 7.3.27. Botiss
    • 7.3.27.1. Company overview
    • 7.3.27.2. Financial performance
    • 7.3.27.3. Product benchmarking
    • 7.3.27.4. Strategic initiatives
  • 7.3.28. Septodont Holding
    • 7.3.28.1. Company overview
    • 7.3.28.2. Financial performance
    • 7.3.28.3. Product benchmarking
    • 7.3.28.4. Strategic initiatives
  • 7.3.29. Implant Direct Corporation (Envista)
    • 7.3.29.1. Company overview
    • 7.3.29.2. Financial performance
    • 7.3.29.3. Product benchmarking
    • 7.3.29.4. Strategic initiatives
  • 7.3.30. META BIOMED CO,. LTD
    • 7.3.30.1. Company overview
    • 7.3.30.2. Financial performance
    • 7.3.30.3. Product benchmarking
    • 7.3.30.4. Strategic initiatives
  • 7.3.31. SigmaGraft Biomaterials
    • 7.3.31.1. Company overview
    • 7.3.31.2. Financial performance
    • 7.3.31.3. Product benchmarking
    • 7.3.31.4. Strategic initiatives
• 7.4. Heat Map Analysis/ Company Market Position Analysis
• 7.5. Estimated Company Market Share Analysis, 2024
• 7.6. List of Other Key Market Players